06Apr 2022
Early-stage Alzheimer disease: getting trial-ready

Early-stage Alzheimer disease: getting trial-ready

Slowing the progression of Alzheimer disease (AD) might be the greatest unmet medical need of our time. Although one AD therapeutic has received a controversial accelerated approval from the FDA, more effective and accessible therapies are urgently needed. For example, in the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease Trial (the first phase III trial to be performed in preclinical AD), 3.5 years and more than 5,900 screens were required to recruit randomize 1,169 participants. A new clinical trials infrastructure is necessary to increase recruitment efficiency and accelerate therapeutic progress. Collaborations in North America, Europe, and Asia address this need by establishing trial-ready cohorts of individuals with preclinical and prodromal AD. These programmes could provide effective tools for pursuing the primary prevention of AD in the future. Here, the study reviews the lessons learned from the AD trial-ready cohorts that have been established to date to inform ongoing and future efforts towards efficient, cost-effective trial recruitment.

  • #neurology

Like

Save

Share